It has been suggested that due to their structural similarities to L-Dopa, catechins may act as competitive inhibitors among the catechol-O-methyltransferase (COMT) pathway and thus attenuate the peripheral metabolism of the PD drug. The gene discussed is COMT; the disease is Parkinson disease.